Earnings summaries and quarterly performance for SANGAMO THERAPEUTICS.
Executive leadership at SANGAMO THERAPEUTICS.
Alexander Macrae
Detailed
President & Chief Executive Officer
CEO
GD
Gregory Davis
Detailed
Head of Research & Technology
ND
Nathalie Dubois-Stringfellow
Detailed
Chief Development Officer
NJ
Nikunj Jain
Detailed
Principal Accounting Officer
PD
Prathyusha Duraibabu
Detailed
Principal Financial Officer (Interim)
SW
Scott Willoughby
Detailed
Chief Legal Officer & Corporate Secretary
Board of directors at SANGAMO THERAPEUTICS.
Research analysts who have asked questions during SANGAMO THERAPEUTICS earnings calls.
MR
Maurice Raycroft
Jefferies Financial Group
3 questions for SGMO
Also covers: ABEO, AFMD, ALNY +14 more
YZ
Yanan Zhu
Wells Fargo Securities
3 questions for SGMO
Also covers: ADAP, AFMD, ARCT +13 more
LI
Luca Issi
RBC Capital Markets
2 questions for SGMO
Also covers: ADVM, ALLO, ALNY +12 more
LS
Luis Santos
H.C. Wainwright & Co.
2 questions for SGMO
Also covers: CMPS, HRMY, MNMD +1 more
NG
Nicole Germino
Truist Securities
2 questions for SGMO
Also covers: CRIS, GILD, INSM +1 more
Gena Wang
Barclays
1 question for SGMO
Also covers: ALNY, BCRX, BLUE +12 more
HW
Huidong Wang
Barclays
1 question for SGMO
Also covers: ALNY, BCRX, BEAM +15 more
JV
James Vane-Tempest
Jefferies Financial Group Inc.
1 question for SGMO
Also covers: AUPH, FMS, SHTPY +1 more
JF
Joshua Fleishman
Cowen and Company, LLC
1 question for SGMO
Also covers: FOLD, KRYS
Patrick Trucchio
H.C. Wainwright & Co.
1 question for SGMO
Also covers: ALT, ARWR, ATAI +13 more
RB
Ritu Baral
TD Cowen
1 question for SGMO
Also covers: ACAD, ALNY, ATAI +11 more
Recent press releases and 8-K filings for SGMO.
Sangamo Therapeutics Announces Underwritten Public Offering and Warrant Amendment
SGMO
- Sangamo Therapeutics, Inc. entered into an underwriting agreement on February 3, 2026, for an offering of 35,190,292 shares of common stock, 17,787,033 pre-funded warrants, and 52,977,325 accompanying purchase warrants.
- The offering is expected to generate approximately $25.0 million in gross proceeds for the company and is anticipated to close on February 4, 2026.
- The combined offering price for each share of common stock and accompanying purchase warrant is $0.4719, while the combined offering price for each pre-funded warrant and accompanying purchase warrant is $0.4619.
- Pre-funded warrants have an exercise price of $0.01 per share and are immediately exercisable.
- Purchase warrants have an exercise price of $0.4719 per share, become exercisable six months after the issuance date (on or after August 4, 2026), and expire five and a half years after the issuance date (on August 4, 2031).
- Concurrently, the company amended outstanding common stock warrants issued on March 26, 2024, reducing their exercise price from $1.00 to $0.4719 for 23,809,523 shares and extending their expiration date to five and a half years from the offering's closing date.
3 days ago
Sangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Data and BLA Submission for Fabry Disease Gene Therapy
SGMO
Product Launch
New Projects/Investments
- Sangamo Therapeutics, Inc. announced on February 3, 2026, the presentation of positive clinical data from its registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease, at the 22nd Annual WORLDSymposiumTM. The U.S. Food and Drug Administration (FDA) had previously agreed in October 2025 that this data could serve as the primary basis for approval under the Accelerated Approval Program.
- Following this, Sangamo initiated a rolling submission of a Biologics License Application (BLA) to the FDA in December 2025 for isaralgagene civaparvovec via the Accelerated Approval pathway.
- Clinical data, with a cutoff date of April 10, 2025, showed a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year at 52 weeks, and all 18 patients on enzyme replacement therapy (ERT) were able to safely withdraw from ERT.
- The treatment was generally well-tolerated, with most adverse events being mild or moderate, and no deaths or study discontinuations due to adverse events reported.
3 days ago
Sangamo Therapeutics Announces Positive STAAR Study Data and BLA Submission for Fabry Disease Gene Therapy
SGMO
New Projects/Investments
Guidance Update
- Sangamo Therapeutics announced detailed positive data from the registrational Phase 1/2 STAAR study for isaralgagene civaparvovec (ST-920), a gene therapy for Fabry disease.
- The study demonstrated a positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks, which the U.S. Food and Drug Administration (FDA) has agreed can serve as the primary basis for approval under the Accelerated Approval pathway.
- A rolling submission of the Biologics License Application (BLA) to the FDA was initiated in December 2025 for ST-920.
- The data supports ST-920's potential as a one-time, well-tolerated, and durable treatment with demonstrated stable cardiac function and sustained alpha-galactosidase A activity for up to 4.5 years.
3 days ago
Sangamo Therapeutics Prices Underwritten Offering
SGMO
- Sangamo Therapeutics announced the pricing of an underwritten offering on February 3, 2026, which includes 35,190,292 shares of common stock and 17,787,033 pre-funded warrants, each sold with an accompanying warrant to purchase one share of common stock.
- The combined offering price for each share of common stock and accompanying warrant is $0.4719, while for each pre-funded warrant and accompanying warrant it is $0.4619.
- The offering is expected to generate approximately $25.0 million in gross proceeds, which Sangamo intends to use for working capital and general corporate purposes.
- Additionally, Sangamo agreed to reduce the exercise price on 23,809,523 outstanding warrants from $1.00 to $0.4719 and extend their term.
4 days ago
Sagimet Biosciences Presents Positive Denifanstat Data at AASLD 2025
SGMO
New Projects/Investments
- Sagimet Biosciences presented two posters at The Liver Meeting® 2025, detailing positive results for denifanstat in treating Metabolic dysfunction-associated steatohepatitis (MASH).
- A secondary analysis of the Phase 2b FASCINATE-2 trial demonstrated that denifanstat improved fibrosis in advanced qF4 MASH patients, with an 85% response rate for \u22651 qFibrosis stage regression compared to 33% for placebo-treated patients.
- In F3 MASH patients, denifanstat achieved a 34% response rate for \u22652 stages of fibrosis improvement without worsening of MASH, significantly higher than the 4% observed in placebo-treated patients.
- Denifanstat also led to decreases in several noninvasive biomarkers in qF4 patients, including FibroScan (-29% vs. placebo +26%) and FAST score (-45% vs. placebo +9%).
Nov 10, 2025, 12:00 PM
Sangamo Provides Q3 2025 Business Update, Highlights Pipeline Progress and Financials
SGMO
Earnings
Guidance Update
New Projects/Investments
- Sangamo reported ~$29.6 million in cash and cash equivalents as of September 30, 2025, with Q3 2025 Non-GAAP Operating Expenses at $33.0 million and full-year 2025 guidance between $125 million and $145 million.
- The company expects a Biologics License Application (BLA) submission for its Fabry disease program (ST-920) as early as Q1 2026, supported by positive clinical data and FDA agreement on an accelerated approval pathway.
- In its neurology pipeline, a Clinical Trial Application (CTA) submission for ST-506 (prion disease) is anticipated as early as mid-2026, with preliminary efficacy data from mid-2027. Patient enrollment has begun for the Phase 1/2 STAND study of ST-503 (chronic neuropathic pain), with preliminary efficacy data expected as early as Q1 2027.
- Sangamo's STAC-BBB platform has generated $88 million in cash from partnerships to date and has the potential for up to $4.6 billion in future milestones and exercise fees from existing agreements.
Nov 6, 2025, 1:30 PM
Sangamo Therapeutics Provides Q3 2025 Pipeline and Funding Update
SGMO
Guidance Update
New Projects/Investments
- Sangamo Therapeutics anticipates its cash and cash equivalents will be sufficient to fund planned operations into the first quarter of 2026.
- The company plans a Biologics License Application (BLA) submission for ST-920 in Fabry disease as early as the first quarter of 2026, following FDA reaffirmation of using EGFR slope for accelerated approval.
- Sangamo has commenced patient enrollment for the Phase I/II ST-503 study in chronic neuropathic pain and is advancing ST-506 for prion disease towards a Clinical Trial Application (CTA) submission as early as mid-2026.
- The company received $6 million from Pfizer for a buyout option and is actively pursuing non-dilutive business development opportunities and capital options to secure long-term funding.
Nov 6, 2025, 1:30 PM
Sangamo Therapeutics Reports Q3 2025 Financial Results and Business Highlights
SGMO
Earnings
Guidance Update
Delisting/Listing Issues
- Sangamo Therapeutics reported a net loss of $34.9 million (or $0.11 per share diluted) on revenues of $0.6 million for Q3 2025, a decrease from $49.4 million in revenues and $10.7 million net income in Q3 2024.
- The company received $6 million from Pfizer and was granted a 180-day extension by Nasdaq until April 27, 2026, to regain compliance with the $1.00 minimum bid price requirement.
- As of September 30, 2025, cash and cash equivalents were $29.6 million, with current funds, including the Pfizer payment and at-the-market proceeds, expected to fund operations into Q1 2026.
- Sangamo is preparing for an anticipated Biologics License Agreement (BLA) submission for its Fabry disease program as early as Q1 2026.
- The company reiterated its 2025 GAAP total operating expenses guidance in the range of $135 million to $155 million.
Nov 6, 2025, 1:05 PM
Quarterly earnings call transcripts for SANGAMO THERAPEUTICS.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more